Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Maxcyte (MXCT) EBITDA (2020 - 2025)

Maxcyte (MXCT) has disclosed EBITDA for 6 consecutive years, with -$13.1 million as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA fell 0.81% to -$13.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$52.5 million, a 1243.09% decrease, with the full-year FY2024 number at -$51.2 million, down 542.86% from a year prior.
  • EBITDA was -$13.1 million for Q3 2025 at Maxcyte, up from -$14.2 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $32.2 million in Q4 2023 to a low of -$14.2 million in Q2 2025.
  • A 5-year average of -$7.5 million and a median of -$10.9 million in 2024 define the central range for EBITDA.
  • Biggest YoY gain for EBITDA was 577.57% in 2023; the steepest drop was 216.85% in 2023.
  • Maxcyte's EBITDA stood at -$5.0 million in 2021, then tumbled by 36.23% to -$6.8 million in 2022, then surged by 577.57% to $32.2 million in 2023, then plummeted by 140.02% to -$12.9 million in 2024, then decreased by 1.48% to -$13.1 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's EBITDA are -$13.1 million (Q3 2025), -$14.2 million (Q2 2025), and -$12.3 million (Q1 2025).